INSYS Therapeutics (INSY) Bullish View Reiterated at Piper Jaffray Following Favorable Buprenorphine Data
Tweet Send to a Friend
Piper Jaffray analyst David Amsellem reiterated an Overweight rating and $28 price target on INSYS Therapeutics (NASDAQ: INSY) reported positive ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
